JP7117015B2 - プラス鎖ｒｎａウイルスによって引き起こされる感染疾患に対するワクチン - Google Patents

プラス鎖ｒｎａウイルスによって引き起こされる感染疾患に対するワクチン Download PDF

Info

Publication number
JP7117015B2
JP7117015B2 JP2019528043A JP2019528043A JP7117015B2 JP 7117015 B2 JP7117015 B2 JP 7117015B2 JP 2019528043 A JP2019528043 A JP 2019528043A JP 2019528043 A JP2019528043 A JP 2019528043A JP 7117015 B2 JP7117015 B2 JP 7117015B2
Authority
JP
Japan
Prior art keywords
virus
rna
dna
vector
jev
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019528043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535291A5 (enExample
JP2019535291A (ja
Inventor
ピーター プシュコ，
イリーナ トレチャコワ，
Original Assignee
メディジェン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディジェン， インコーポレイテッド filed Critical メディジェン， インコーポレイテッド
Publication of JP2019535291A publication Critical patent/JP2019535291A/ja
Publication of JP2019535291A5 publication Critical patent/JP2019535291A5/ja
Priority to JP2021178709A priority Critical patent/JP2022023198A/ja
Application granted granted Critical
Publication of JP7117015B2 publication Critical patent/JP7117015B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019528043A 2016-11-28 2017-11-21 プラス鎖ｒｎａウイルスによって引き起こされる感染疾患に対するワクチン Active JP7117015B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021178709A JP2022023198A (ja) 2016-11-28 2021-11-01 プラス鎖ｒｎａウイルスによって引き起こされる感染疾患に対するワクチン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662426708P 2016-11-28 2016-11-28
US62/426,708 2016-11-28
PCT/US2017/062733 WO2018098133A1 (en) 2016-11-28 2017-11-21 Vaccines against infectious diseases caused by positive stranded rna viruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021178709A Division JP2022023198A (ja) 2016-11-28 2021-11-01 プラス鎖ｒｎａウイルスによって引き起こされる感染疾患に対するワクチン

Publications (3)

Publication Number Publication Date
JP2019535291A JP2019535291A (ja) 2019-12-12
JP2019535291A5 JP2019535291A5 (enExample) 2020-11-12
JP7117015B2 true JP7117015B2 (ja) 2022-08-12

Family

ID=62195325

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019528043A Active JP7117015B2 (ja) 2016-11-28 2017-11-21 プラス鎖ｒｎａウイルスによって引き起こされる感染疾患に対するワクチン
JP2021178709A Withdrawn JP2022023198A (ja) 2016-11-28 2021-11-01 プラス鎖ｒｎａウイルスによって引き起こされる感染疾患に対するワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021178709A Withdrawn JP2022023198A (ja) 2016-11-28 2021-11-01 プラス鎖ｒｎａウイルスによって引き起こされる感染疾患に対するワクチン

Country Status (7)

Country Link
US (3) US11058759B2 (enExample)
EP (1) EP3545083A4 (enExample)
JP (2) JP7117015B2 (enExample)
KR (1) KR102511472B1 (enExample)
CN (1) CN110088273B (enExample)
MY (1) MY199945A (enExample)
WO (1) WO2018098133A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024500917A (ja) * 2020-12-22 2024-01-10 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 抗原特異的人工免疫制御性Ｔ（ａｉｒＴ）細胞
CN117321069A (zh) 2021-03-23 2023-12-29 百洛克株式会社 基于减毒呼肠孤病毒的疫苗组合物及其用途
CN114807232A (zh) * 2022-05-12 2022-07-29 中国人民解放军海军军医大学 一株西尼罗病毒感染性克隆的构建及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523189A (ja) 2000-02-16 2003-08-05 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ，センターズ フォー 無毒性の免疫原性フラビウイルスキメラ
US20070128711A1 (en) 2005-12-05 2007-06-07 Yamshchikov Vladimir F Chimeric west nile viruses and uses thereof
JP2015535302A (ja) 2012-11-07 2015-12-10 サザン・リサーチ・インスティテュート ビリオン分解に影響を及ぼすフラビウイルスのエンベロープタンパク質変異

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102600481A (zh) * 2012-03-20 2012-07-25 中国农业科学院哈尔滨兽医研究所 腺病毒/日本脑炎病毒复制子嵌合载体猪瘟疫苗及其应用
CN103088049A (zh) * 2012-12-26 2013-05-08 中国人民解放军军事医学科学院生物工程研究所 日本脑炎病毒sa14-14-2株基于dna的感染性克隆、其构建方法及应用
US10369209B2 (en) 2014-04-11 2019-08-06 Utah State University Drug target and construct for Japanese encephalitis virus infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523189A (ja) 2000-02-16 2003-08-05 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ，センターズ フォー 無毒性の免疫原性フラビウイルスキメラ
US20070128711A1 (en) 2005-12-05 2007-06-07 Yamshchikov Vladimir F Chimeric west nile viruses and uses thereof
JP2015535302A (ja) 2012-11-07 2015-12-10 サザン・リサーチ・インスティテュート ビリオン分解に影響を及ぼすフラビウイルスのエンベロープタンパク質変異

Also Published As

Publication number Publication date
US20190314482A1 (en) 2019-10-17
US20210322535A1 (en) 2021-10-21
CN110088273A (zh) 2019-08-02
US11058759B2 (en) 2021-07-13
US20250057932A1 (en) 2025-02-20
EP3545083A1 (en) 2019-10-02
KR102511472B1 (ko) 2023-03-16
EP3545083A4 (en) 2020-06-24
JP2019535291A (ja) 2019-12-12
CN110088273B (zh) 2024-03-05
MY199945A (en) 2023-11-30
JP2022023198A (ja) 2022-02-07
WO2018098133A1 (en) 2018-05-31
KR20190092468A (ko) 2019-08-07

Similar Documents

Publication Publication Date Title
JP5538729B2 (ja) 偽感染性フラビウイルスおよびそれらの使用
US20250057932A1 (en) Vaccines against infectious diseases caused by positive stranded rna viruses
EP3158059B1 (en) Method for rapid generation of an attenuated rna virus
Nickols et al. Plasmid DNA launches live-attenuated Japanese encephalitis virus and elicits virus-neutralizing antibodies in BALB/c mice
WO2018129160A1 (en) Live attenuated flavivirus vaccines and methods of using and making same
Yamshchikov et al. Development of a human live attenuated West Nile infectious DNA vaccine: Suitability of attenuating mutations found in SA14-14-2 for WN vaccine design
CA3168673A1 (en) Coronavirus vaccines
US20070036827A1 (en) West nile virus vaccine
EP3846847A1 (en) Chimeric flavivirus lyssavirus vaccines
AU2009211379B2 (en) Flaviviridae mutants comprising a deletion in the capsid protein for use as vaccines
WO2020077395A1 (en) Virus vaccine
Kuznetsova et al. Development and characterization of chimera of yellow fever virus vaccine strain and Tick-Borne encephalitis virus
TWI835787B (zh) 在ｖｅｒｏ細胞上生長之減毒活黃熱病病毒株及包含其之疫苗組成物
CN101084010A (zh) 抗日本脑炎病毒及西尼罗病毒的疫苗
RU2788130C2 (ru) Живой аттенуированный штамм вируса желтой лихорадки, адаптированный к росту в клетках vero, и вакцинная композиция, содержащая его
Kuznetsova et al. Development and Characterization of Yellow Fever Virus Vaccine Strain 17DD-Based Chimeric Tick-Borne Encephalitis Virus
US11351240B2 (en) Chimeric yellow fever ZIKA virus strain
Monath Recombinant, chimeric, live, attenuated vaccines against flaviviruses and alphaviruses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201002

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220725

R150 Certificate of patent or registration of utility model

Ref document number: 7117015

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250